SUO 2017: Advanced Imaging in Prostate Cancer: PET/MRI of Prostate Cancer
Washington, DC (UroToday.com) In this session, Dr. Ippolito discussed the frontier of PET/MRI and its potential use in evaluation of patients with prostate cancer. While PET has poor anatomic detail and special resolution it has excellent sensitivity and molecular imaging to identify recurrence or metastasis and ensure accurate diagnostics.
SUO 2017: 68Ga-PSMA Imaging in Prostate Cancer and the Promise of Radio-Ligands for Targeted Treatment
Washington, DC (UroToday.com) PSMA, a type II glycoprotein, is found to be overexpressed in prostate cancer cells and its expression level has been correlated with disease aggressiveness making the transmembrane protein an ideal target for prostate cancer imaging. Dr. Reiter, from UCLA, discusses the use of 68Ga-PSMA in the imaging of prostate cancer.
SUO 2017: PSMA-targeted PET Imaging of Prostate Cancer with Fluorinated Radiotracers
Washington, DC (UroToday.com) Dr. Gorin from Johns Hopkins presented a helpful overview of PSMA-based prostate cancer (PC) imaging modalities currently in use. PSMA is a transmembrane protein that is over-expressed by prostate cancer epithelial cells, and is estimated to be present in 95% of all prostate cancer cells. Agents that target PSMA have long been shown to have excellent sensitivity and specificity in the detection of PC. However, different agents targeting PSMA have different test characteristics.
SUO 2017: Advanced Imaging in Prostate Cancer: [11C] Choline
Washington, DC (UroToday.com) Dr. Karnes gave a review of the history of [11C] Choline PET/CT and its use in prostate cancer. [11C] Choline is a nutrient located in the lipid bi-layer of cell membranes that has been shown to have elevated levels in neoplastic cells. It has less urine excretion than 18F and a shorter half-life.
SUO 2017: Advanced Imaging in Prostate Cancer: [18F] FACBC
Washington, DC (UroToday.com) Dr. Nieh from Emory University presented an excellent overview of a new PET radiotracer [18F] FACBC, generically known as fluciclovine (Axumin®). FACBC is an amino acid derivative radiotracer that was originally used in brain studies. Due to limited renal excretion, it was studied as an imaging exam for kidney cancer. However, its utility in metastatic prostate cancer (PC) was quickly realized.
SUO 2017: A Novel Target for Imaging of Prostate Cancer
Washington, DC (UroToday.com) The discovery of other targets for the imaging of prostate cancer continues to evolve Dr. Thakur, from the Jefferson Department of Radiology, presented the novel use of the VAPC-1 receptor as a novel target for prostate cancer imaging.